GSA Capital Partners LLP lowered its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 33.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 153,239 shares of the company's stock after selling 78,496 shares during the quarter. GSA Capital Partners LLP owned approximately 0.07% of Cellebrite DI worth $2,581,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC grew its holdings in Cellebrite DI by 28.6% during the 3rd quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company's stock worth $152,000 after acquiring an additional 2,000 shares during the last quarter. Meritage Portfolio Management grew its holdings in Cellebrite DI by 12.0% during the 3rd quarter. Meritage Portfolio Management now owns 27,831 shares of the company's stock worth $469,000 after acquiring an additional 2,973 shares during the last quarter. Principal Financial Group Inc. bought a new stake in Cellebrite DI during the 3rd quarter worth about $23,402,000. Harbor Capital Advisors Inc. boosted its stake in shares of Cellebrite DI by 96.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 95,351 shares of the company's stock valued at $1,606,000 after purchasing an additional 46,727 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its stake in shares of Cellebrite DI by 8.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 51,155 shares of the company's stock valued at $861,000 after purchasing an additional 3,912 shares during the last quarter. Institutional investors own 45.88% of the company's stock.
NASDAQ CLBT opened at $18.37 on Tuesday. Cellebrite DI Ltd. has a 12-month low of $7.32 and a 12-month high of $21.00. The company has a market capitalization of $3.78 billion, a PE ratio of -11.85, a price-to-earnings-growth ratio of 2.52 and a beta of 1.50. The firm's 50 day moving average is $17.62 and its 200-day moving average is $14.34.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.05. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The company had revenue of $106.90 million for the quarter, compared to the consensus estimate of $102.06 million. During the same period last year, the company earned $0.09 earnings per share. The firm's revenue was up 27.0% compared to the same quarter last year. As a group, sell-side analysts expect that Cellebrite DI Ltd. will post 0.31 EPS for the current year.
Several brokerages have recently issued reports on CLBT. Bank of America raised their target price on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, August 16th. JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $21.00 to $22.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Lake Street Capital raised their target price on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Craig Hallum raised their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Finally, TD Cowen raised their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a "buy" rating in a research note on Monday, September 23rd. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $20.29.
Read Our Latest Research Report on CLBT
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.